Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Субъединичные вакцины против новых патогенных коронавирусов человека
2020-02-28
SCID: 54.1/6qbjaw33
Discuss with AI
Emerging human coronavirusesMERS-CoVReceptor-binding domainSARS-CoVSubunit vaccines
Figures from the paper
Abstract (AI)
Seven coronaviruses (CoVs) have been isolated from humans so far. Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health. SARS-CoV infection in humans (with about 10% case fatality rate) was first reported from China in 2002, while MERS-CoV infection in humans (with about 34.4% case fatality rate) was first reported from Saudi Arabia in June 2012. 2019-nCoV was first reported from China in December 2019, and is currently infecting more than twenty thousand people (with about 2.1% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S structural proteins, and the potential factors affecting these subunit vaccines are also illustrated. Overall, this review will be helpful for rapid design and development of vaccines against the new 2019-nCoV and any future CoVs with pandemic potential. This review was written for the topic of Antivirals for Emerging Viruses: Vaccines and Therapeutics in the Virology section of Frontiers in Microbiology.
Key Findings
1
No vaccine against 2019-nCoV was available at the time of the review, and no SARS-CoV or MERS-CoV vaccine had received approval for human use.
2
Subunit vaccine approaches against SARS-CoV and MERS-CoV have targeted full-length spike protein, receptor-binding domain, non-RBD spike fragments, and non-spike structural proteins.
3
The review identifies factors influencing subunit-vaccine performance and synthesizes advances intended to support rapid vaccine design against 2019-nCoV and future pandemic-potential coronaviruses.
4
Three emerging human coronaviruses—SARS-CoV, MERS-CoV, and 2019-nCoV—pose major public-health threats, with reported case-fatality rates of approximately 10%, 34.4%, and 2.1%, respectively.
Research Object
Subunit vaccines against emerging pathogenic human coronaviruses, particularly SARS-CoV, MERS-CoV, and 2019-nCoV
Research Subject
The design, development, types, structural bases, and factors affecting the efficacy and applicability of subunit vaccines targeting key proteins and protein fragments of emerging human coronaviruses
Publication Details
Publication Date
2020-02-28
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest